

One of the five NRC recommended attributes that will be used to characterize a contaminant's known or potential ability to cause a health effect

Severity

Answers the question: How bad is the effect?

Process





Applied scale to sample data set

Assessed scoring difficulties



Revised scale to resolve difficulties

3



Completed three cycles of review/revision process

Guiding Principles

Severity was scored based on the critical effect associated with the selected potency value (e.g.- RfD, NOAEL, LOAEL, LD₅₀)

Definition:

- Critical Effect- The first adverse effect, or its known precursor, that occurs to the most sensitive species as the dose rate of an agent increases.

Descriptions of critical effects were used exactly as found in IRIS database.

4



For chemicals having multiple critical effects, each effect was scored. The highest score prevailed.

Types of Critical Effect Descriptors

| Chemical Contaminant | RfD | IRIS critical effect |
|-------------------------|----------|---|
| Fenamiphos | 2.5E-04 | Cholinesterase inhibition (ChE) |
| 2,4-dinitrophenol | 2.00E-03 | Cataract formation |
| Chlordane | 5.00E-04 | Hepatic necrosis |
| Dicamba | 3.00E-02 | Maternal & Fetal toxicity |
| 2,4-dinitrotoluene | 2.00E-03 | Neurotoxicity, Heinz bodies and biliary tract hyperplasia |

NRC Scoring Scheme*

. () -

| 0 | No Effect | 6 | Irreversible changes; treatable |
|---|--|-----|--|
| 1 | Changes in organ weights | | disease |
| | with minimal clinical significance | 7 | Single organ system pathology and function loss |
| 2 | Biochemical changes with minimal clinical significance | 8 | Multiple organ system pathology and function loss |
| 3 | Pathology of minimal clinical | 9 | Disease likely leading to death |
| | significance | 10 | Death |
| 4 | Cellular changes that could lead to disease; minimal functional change | | |
| 5 | Significant functional changes | * C | ee Table I |
| | that are reversible | 3 | |
| | | | |
| | | | 6 |

| Scoring Sc | ale: | Revision 1 |
|------------|----------|---|
| (Table II) | 0 | |
| | <u> </u> | 1 Cosmetic Effects |
| $-\phi$ | 2 | 2 Transient, reversible effects |
| | 3 | 3 Cellular/physiological changes that could lead to disease/disorder (risk factors or precursor effects) |
| Refined | 4 | 4 Mild, permanent functional changes |
| Added - | 5 | 5 Curable diseases or disorders |
| | 6 | 6 Treatable, uncurable diseases or disorders |
| | 7 | 7 Chronic, untreatable, nonlethal diseases or disorders |
| | ▶ 8 | |
| | 9 | 9 Disease likely leading to death |
| | 1 | 10 Death 7 |

Scoring Scale: Revision 2 (Table III)

| 0 | No Effect | | Significant, irreversible |
|---|--|---|--|
| 1 | Cosmetic Effects | | disorders that can be |
| 2 | Transient, reversible effects; | | managed by medical treatment |
| | differences in organ weights, body weights or changes in biochemical | 6 | Significant, irreversible, non- |
| | parameters with minimal clinical | | lethal conditions or disorders |
| | significance | | that cannot be managed by medical treatment |
| 3 | Cellular/physiological changes that | 7 | Developmental or |
| | could lead to disorders (risk factors | | reproductive effects leading to |
| | or precursor effects) | | major dysfunction |
| 4 | Significant functional changes that | 8 | Disorder likely leading to |
| | are reversible or permanent | | death |
| | changes of minimal toxicological | 9 | Death |
| | significance | | |
| | | | |
| | | | |
| | | | 8 |

Scoring Scale: Revision 3 (Table IV)

| 1 | No adverse effect | | |
|---|---|---|-----------------------------------|
| 2 | Cosmetic effects | 6 | Significant, irreversible, |
| 3 | Reversible effects; differences in organ weights, body | | nonlethal conditions or disorders |
| | weights or changes in biochemical parameters with minimal clinical significance | 7 | Developmental or |
| | | | reproductive effects leading to |
| | | | major dysfunction |
| 4 | Cellular/physiological changes that could lead to disorders (risk factors or precursor effects) | 8 | Tumors or disorders likely |
| | | | leading to death |
| | | 9 | Death |
| 5 | Significant functional changes that are reversible or permanent changes of minimal toxicological significance | | |
| | | | 9 |

Scoring/Binning Exercise (Table IV)

100 chemicals with RfDs in IRIS database



 Further improve scoring scheme by scoring actual effects as they can be downloaded from IRIS

- Experiment with "binning" of critical effects
- Begin developing a "working vocabulary" or glossary of critical effect descriptors

Examples of Critical Effects: Results of "Binning Exercise"

| 1 | No adverse effects |
|---|---|
| | No observed adverse effects |
| 2 | Abnormal appearance |
| 3 | Cholinesterase inhibition |
| | Salivation, Clinical parameters, |
| | Increased relative organ weights, Increased enzymes |
| 4 | Decreased blood counts, Hypothermia, Liver cell enlargement |
| 5 | GI irritation, GI bleeding, Tremors |
| | |

| 6 | Kidney damage(unspecified), Cardiac toxicity, Spleen toxicity | | | | |
|-----------------------------------|--|--|--|--|--|
| 7 | Testicular effects, Spermatogenic arrest, Lower ovarian weight | | | | |
| 8 | Decreased longevity | | | | |
| 9 Mortality, Increased mortality, | | | | | |
| | Decreased survival | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | 11 | | | | |

On-going Issues

Middle scores remain difficult to differentiate

Difficulties in placing different types of reproductive and developmental effects

How to score chemicals lacking critical effects

Next Steps

Expand "binning" exercises to include data sources other than IRIS and continue to develop a glossary of terms

13

 Continue to revise scoring scheme based on lessons learned

Questions to Consider

Should scale be condensed to contain fewer categories?

Should "death" be included as separate category? (possibly useful for LD₅₀)